Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • CTF 2025

Children’s Tumor Foundation’s Annual NF Conference

June 21 - 24, 2025 

  1. All
  2. NF1-PN

PDF

Adult patient and caregiver perspectives on the impact of Neurofibromatosis Type 1-associated Plexiform Neurofibroma (NF1-PN): insights from a US qualitative survey

PDF

A phase 1/2 study of the pharmacokinetics and safety of the selumetinib granule formulation in children aged ≥1 to <7 years with NF1-PN: Primary analysis of the SPRINKLE study (NCT05309668)

PDF

Characteristics of patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Japan and real-world safety and effectiveness of selumetinib: A 1-year interim analysis of an all-case postmarketing surveillance study

PDF

Healthcare providers' perspectives on the management of adults with Neurofibromatosis Type 1 and Plexiform Neurofibroma: Insights from a US survey

PDF

Proteomic analysis to study selumetinib effect in adolescents with Neurofibromatosis Type-1 and inoperable Plexiform Neurofibroma

PDF

Real-world outcomes of selumetinib in chinese paediatric patients with inoperable Neurofibromatosis Type 1-associated Plexiform Neurofibroma (NF1-PN): Interim analysis of baseline characteristics from the PEDIA study

PDF

The development and evaluation of a patient and carer guide for selumetinib treatment in Neurofibromatosis Type 1 in the UK.

PDF

Adult patient and caregiver perspectives on the impact of Neurofibromatosis Type 1-associated Plexiform Neurofibroma (NF1-PN): insights from a US qualitative survey

PDF

A phase 1/2 study of the pharmacokinetics and safety of the selumetinib granule formulation in children aged ≥1 to <7 years with NF1-PN: Primary analysis of the SPRINKLE study (NCT05309668)

PDF

Characteristics of patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Japan and real-world safety and effectiveness of selumetinib: A 1-year interim analysis of an all-case postmarketing surveillance study

PDF

Healthcare providers' perspectives on the management of adults with Neurofibromatosis Type 1 and Plexiform Neurofibroma: Insights from a US survey

PDF

Proteomic analysis to study selumetinib effect in adolescents with Neurofibromatosis Type-1 and inoperable Plexiform Neurofibroma

PDF

Real-world outcomes of selumetinib in chinese paediatric patients with inoperable Neurofibromatosis Type 1-associated Plexiform Neurofibroma (NF1-PN): Interim analysis of baseline characteristics from the PEDIA study

PDF

The development and evaluation of a patient and carer guide for selumetinib treatment in Neurofibromatosis Type 1 in the UK.

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States